• 1
    Jung MJ, Palfreyman MG. Vigabatrin: mechanisms of action. In: LevyRH, MattsonRH, MeldrumBS, eds. Antiepileptic drugs. 4th ed. New York : Raven Press, 1995:90313.
  • 2
    Schousboe A, Larsson OM, Seiler N. Stereoselective uptake of the GABA-transaminase inhibitors gamma-vinyl GABA and gamma-acetylenic GABA into neurons and astrocytes. Neurochem Res 1986;11:1497505.
  • 3
    Petroff OAC, Rothman DL, Behar KL, Mattson RH. Human brain GABA levels rise after initiation of vigabatrin therapy but fail to rise further with increasing dose. Neurology 1996;46:145963.
  • 4
    Schechter PJ, Hanke NFJ, Grove J, Huebert N, Sjoerdsma A. Biochemical and clinical effects of gamma-vinyl-GABA in patients with epilepsy. Neurology 1984;34:1826.
  • 5
    Ben-Menachem E, Persson LI, Schechter PJ, et al. The effect of different vigabatrin treatment regimens on CSF biochemistry and seizure control in epileptic patients. Br J Clin Pharmacol 1989;27 (suppl 1):79S85S.
  • 6
    Ben-Menachem E, Persson LI, Mumford JP, Haegele KD, Huebert N. The effect of long-term vigenetrin therapy on selected neuro-transmitter concentrations in cerebrospinal fluid. J Child Neurol 1991;6(suppl 2):2S116.
  • 7
    Reikkinen PJ, Ylinen A, Halonen T, Sivenius J, Pitkänen A. Cerebrospinal fluid GABA and seizure control with vigabatrin. Br J Clin Pharmacol 1989;27(suppl 1):87S94S.
  • 8
    Kälviäinen R, Halonen T, Pitkänen A, Reikkinen PJ. Amino acid levels in the cerebrospinal fluid of newly diagnosed epileptic patients: effect of vigabatrin and carbamazepine monotherapies. J Neurochem 1993;60:124450.
  • 9
    Barnes EM Jr. Use-dependent regulation of GABAA receptors. Int Rev Neurobiol 1996;39:5376.
  • 10
    Nadler LS, Guirguis ER, Siegel RE. GABAA receptor subunit polypeptides increase in parallel but exhibit distinct distributions in the developing rat cerebellum. J Neurobiol 1994;25:153344.
  • 11
    Belhage B, Hansen GH, Meier E, Schoesboe A. Effects of inhibitors of protein synthesis and intracellular transport on the GABA-agonist induced functional differentiation of cultured cerebellar granule cells. J Neurochem 1990;55:110713.
  • 12
    Kim HY, Sapp DW, Olsen RW, Tobin AJ. GABA alters GABAA receptor mRNAs and increases ligand binding. J Neurochem 1993;61:23347.
  • 13
    Schmid L, Bottlaender M, Brouillet E, Fuseau C, Mazière M. Vigabatrin modulates benzodiazepine activity in vivo: a positron emission tomography study in baboon. J Pharmacol Exp Ther 1996;276:97783.
  • 14
    Weber OM, Verhagen A, Due CO, Meier D, Leenders KL, Boesiger P. Effects of vigabatrin on GABA-ergic cycle as determined by MRS and PET [Abstract]Physics Biol Med 1997;5(suppl):67.
  • 15
    Prevett MC, Lammertsma AA, Brooks DJ, et al. Benzodiazepine-GABAA receptors in idiopathic generalized epilepsy measured with [11C]flumazenil and positron emission tomography. Epilepsia 1995;36:11321.
  • 16
    McLean MJ, MacDonald RL. Sodium valproate, but not ethosuximide, produces use- and voltage-dependent limitation of high frequency repetitive firing of action potentials of mouse central neurons in cell culture. J Pharmacol Exp Ther 1986;237:100111.
  • 17
    Schechter PJ, Tranier Y, Grove J. Effect of n-dipropylacetate on amino acid concentrations in mouse brain: correlation with anti-convulsant activity. J Neurochem 1987;31:13257.
  • 18
    Gram L, Larsson OM, Johnsen AH, et al. Effects of valproate, vigabatrin and aminooxyacetic acid on release of endogenous and exogenous GABA from cultured neurons. Epilepsy Res 1988;2:8795.
  • 19
    Schubiger PA, Hasler PH, Beer-Wohlfahrt H, et al. Evaluation of a multicentre study with iomazenil: a benzodiazepine receptor ligand. Nucl Med Commun 1991;12:56982.
  • 20
    Laruelle M, Baldwin RM, Rattner Z, et al. SPECT quantification of [123I]iomazenil binding to benzodiazepine receptors in nonhuman primates: II. Equilibrium analysis of constant infusion experiments and correlation with in vitro parameters. J Cereb Blood Flow Metab 1994;14:45365.
  • 21
    Abi-Dargham A, Laruelle M, Seibyl J, et al. SPECT measurement of benzodiazepine receptors in human brain with [123I]iomazenil: kinetic and equilibrium paradigms. J Nucl Med 1994;35:22838.
  • 22
    Rothman DL, Petroff OAC, Behar KL, Mattson RH. Localized 1H NMR measurements of gamma-aminobutyric acid in human brain in vivo. Proc Natl Acad Sci USA 1993;90:56626.
  • 23
    Zoghbi SS, Baldwin RM, Seibyl JP, et al. Pharmacokinetics of the SPECT benzodiazepine receptor radioligand [123]iomazenil in human and nonhuman primates. Nucl Med Biol 1992;19:5.
  • 24
    Friston KJ, Ashburner J, Poline JB, Frith CD, Heather JD, Frackowiak RSL. Spatial registration and normalisation of images. Hum Brain Mapp 1995;22:16589.
  • 25
    Rajeevan N, Zubal IG, Ramsby SQ, Zoghbi SS, Seibyl JP, Innis RB. Significance of nonuniform attenuation correction in quantitative brain SPECT imaging. J Nucl Med 1998;39:171926.
  • 26
    Fujita M, Verhoeff NPLG, Baldwin RM, et al. Reproducibility of [I-123]iomazenil equilibrium measurement of benzodiazepine receptors [Abstract]. J Nucl Med 1998;208P.
  • 27
    Frey KA, Minoshima S, Koeppe RA, Kilbourn MR, Berger KL, Kuhl DE. Stereotaxic summation analysis of human cerebral benzodiazepine binding maps. J Cereb Blood Flow Metab 1996;16:40917.
  • 28
    Koepp MJ, Richardson MP, Brooks DJ, et al. Cerebral benzodiazepine receptors in hippocampal sclerosis. Brain 1996;119:167787.
  • 29
    Koepp MJ, Richardson MP, Labbé C, et al. 11C-flumazenil PET, volumetric MRI, and quantitative pathology in mesial temporal lobe epilepsy. Neurology 1997;49:76473.
  • 30
    Richardson MP, Koepp MJ, Brooks DJ, Fish DR, Duncan JS. Benzodiazepine receptors in focal epilepsy with cortical dysgenesis: a 11C-flumazenil PET study. Ann Neurol 1996;40:18898.
  • 31
    Maloteaux JM, Octave JN, Gossuin A, Laterre C, Trouet A. GABA induces down-regulation of the benzodiazepine-GABA receptor complex in the rat cultured neurons. Eur J Pharmacol 1987;144:17383.
  • 32
    Fujita M, Woods SW, Verhoeff NPLG, et al. Changes of benzodiazepine receptors during chronic benzodiazepine administration in humansEur J Pharmacol 1999;368:16172.
  • 33
    Machin D, Campbell MJ. Statistical tables for the design of clinical trials. Oxford , England : Blackwell Scientific Publications, 1987.
  • 34
    Houston AS, Kemp PM, Macleod MA. A method for assessing the significance of abnormalities in HMPAO brain SPECT images. J Nucl Med 1994;35:23944.
  • 35
    Abi-Dargham A, Laruelle M, Krystal J, et al. No evidence of altered in vivo benzodiazepine receptor binding in schizophrenia. Neuropsychopharmacology 1999;20:65061.
  • 36
    Weeks RA, Cunningham VJ, Piccini P, Waters S, Harding AE, Brooks DJ. 11C-diprenorphine binding in Huntington's disease: a comparison of region of interest analysis with statistical parametric mapping. J Cereb Blood Flow Metab 1997;17:9439.
  • 37
    Wright IC, Ellison ZR, Sharma T, Friston KJ, Murray RM, McGuire PK. Mapping of grey matter changes in schizophrenia. Schizophr Res 1999;35:114.